Diagnosis of disorders in the coagulation system, assessment of the risk of hemorrhagic complications in severe cirrhosis/liver diseases according to global screening tests of the hemostasis system and principles for their correction: guidelines

Author:

Maevskaya M. V.1ORCID,Zharkova M. S.1ORCID,Ivashkin V. T.1ORCID,Bessonova E. N.2ORCID,Geyvandova N. I.3ORCID,Kitsenko E. A.4ORCID,Korochanskaya N. V.5ORCID,Kurkina I. A.1ORCID,Melikyan A. L.6ORCID,Morozov V. G.7ORCID,Khoronko Yu. V.8ORCID

Affiliation:

1. Sechenov First Moscow State Medical University (Sechenov University)

2. Sverdlovsk Regional Clinical Hospital No. 1

3. Stavropol State Medical University

4. Russian Scientific Center of Surgery named after academician B.V. Petrovsky

5. Kuban State Medical University; Regional Clinical Hospital No. 2

6. National Medical Research Center for Hematology

7. Medical Company “Hepatologist”

8. Rostov State Medical University

Abstract

Hemostasis disorders in cirrhosis / severe liver disease are complex, as they affect both pro- and anticoagulant factors, as well as pro- and antifibrinolytic components. Most of the tests that are used in clinical practice to assess coagulation do not take into account the compensatory capabilities of this system as a whole. This document provides guidance for the optimal application and interpretation of global screening tests in the assessment of hemostasis in cirrhosis/severe liver disease, analysis of risk factor of spontaneous and perioperative hemorrhagic complications in these patients, and possible ways to correct them. Thrombocytopenia is one of the most common hematological abnormalities in cirrhosis/ severe liver disease. The frequency of thrombocytopenia in such patients at the stage of liver cirrhosis is 70%, at the pre-cirrhotic stage – 6%. The latest scientific data on the use of thrombopoietin receptor agonists in chronic liver diseases are presented: which patients are the best candidates for a such of therapy. The rationality and limitations in prescribing blood components to patients with liver cirrhosis/severe liver diseases are described. Emphasis is placed on the fact that a number of hemorrhagic complications develop for other non-coagulopathic reasons: decompensated portal hypertension, traumatization of a varicose vein with trophic wall disorders, etc. Data are presented on the use of viscoelastic tests to optimize the management of patients with liver cirrhosis, which simultaneously assess the four main known components of the hemostasis system: the coagulation cascade, platelets, anticoagulant mechanisms and the fibrinolysis system. These tests allow optimization of transfusion of blood components in such patients and should be further studied. Research in this very complex area of hepatology is ongoing and must continue.

Publisher

Remedium, Ltd.

Subject

General Medicine

Reference32 articles.

1. Blasi A. Coagulopathy in liver disease: Lack of an assessment tool. World J Gastroenterol. 2015;21(35):10062–10071. https://doi.org/10.3748/wjg.v21.i35.10062.

2. Ivashkin V.T., Maevskaya M.V., Zharkova M.S., Zhigalova S.B., Kitsenko E.A., Manuk'yan G.V., Tikhonov I.N. Tsirroz i fibroz pecheni: klinicheskie rekomendatsii. M.; 2021. 99 s. Rezhim dostupa: https://cr.minzdrav.gov.ru/schema/715_1. Ivashkin V.T., Maevskaya M.V., Zharkova M.S., Zhigalova S.B., Kitsenko E.A., Manukyan G.V., Tikhonov I.N. Cirrhosis and fibrosis of the liver: clinical guidelines. Moscow; 2021. 99 p. (In Russ.) Available at: https://cr.minzdrav.gov.ru/schema/715_1.

3. Moore A.H. Thrombocytopenia in Cirrhosis: A Review of Pathophysiology and Management Options. Clin Liver Dis (Hoboken). 2019;14(5):183–186. https://doi.org/10.1002/cld.860.

4. Peck-Radosavljevic M. Thrombocytopenia in liver disease. Can J Gastroenterol. 2000;14(Suppl. D):60D–66D. https://doi.org/10.1155/2000/617428.

5. Reverter J.C. Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? Yes. J Thromb Haemost. 2006;4(4):717–720. https://doi.org/10.1111/j.1538-7836.2006.01887.x.

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3